IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease

Mouse Studies Demonstrate Significant Reduction in Amyloid Plaque: 78% in Cortex and 85% in Hippocampus

On June 25, 2024, IGC Pharma, Inc. (NYSE American: IGC) announced encouraging preclinical results in an Alzheimer’s mouse model demonstrating the potential of the company’s therapeutic candidate, TGR-63, to combat Alzheimer's disease. "These preclinical results for TGR-63 are highly encouraging. The significant reduction in amyloid plaque burden in an Alzheimer’s mouse model observed in this study suggests TGR-63 has the potential to be a transformative treatment for Alzheimer's disease. TGR-63 is filed for patent protection in U.S. patent application (USPTO Patent Application Number: 18/006,578), further strengthening its potential value. We are committed to advancing TGR-63 through clinical trials to determine its efficacy and safety in human patients, offering new hope for the 50 million individuals affected by this devastating illness," said Ram Mukunda, CEO of IGC Pharma. (Editor’s note: IGC is India Globalization Capital.)

Login Or Register To Read Full Story